Nexstim
Founded Year
2000Stage
IPO | IPOTotal Raised
$34.11MDate of IPO
11/5/2014Market Cap
0.02BStock Price
2.69About Nexstim
Nexstim is a medical technology company with a focus on non-invasive brain stimulation technology. The company offers products that provide personalized and effective therapies and diagnostics for challenging brain diseases and disorders, such as major depressive disorder and chronic neuropathic pain. Its primary customers are in the healthcare industry, particularly those dealing with neurosurgery and mental health. It was founded in 2000 and is based in Helsinki, Finland.
Loading...
Loading...
Nexstim Patents
Nexstim has filed 23 patents.
The 3 most popular patent topics include:
- neuropsychology
- neuroscience
- electrotherapy
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/27/2019 | 3/8/2022 | Neurotechnology, Neurophysiology, Neuropsychology, Electrotherapy, Neuroscience | Grant |
Application Date | 5/27/2019 |
|---|---|
Grant Date | 3/8/2022 |
Title | |
Related Topics | Neurotechnology, Neurophysiology, Neuropsychology, Electrotherapy, Neuroscience |
Status | Grant |
Latest Nexstim News
Nov 30, 2023
About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain. Nexstim shares are listed on Nasdaq First North Growth Market Finland. For more information, please visit www.nexstim.com Attachment
Nexstim Frequently Asked Questions (FAQ)
When was Nexstim founded?
Nexstim was founded in 2000.
Where is Nexstim's headquarters?
Nexstim's headquarters is located at Elimäenkatu 9 B, Helsinki.
What is Nexstim's latest funding round?
Nexstim's latest funding round is IPO.
How much did Nexstim raise?
Nexstim raised a total of $34.11M.
Who are the investors of Nexstim?
Investors of Nexstim include HealthCap Venture Capital, Finnish Industry Investment, Sitra Ventures, Lundbeckfond Ventures, Ilmarinen Pension Insurance and 6 more.
Loading...
Loading...